pembrolizumab

BioInvent's CMO comments on phase I/IIa data with BI-1808

BioInvent's Phase I/IIa study with the first-in-class anti-TNFR2 antibody BI-1808 in advanced cancer has yielded positive results. The strong interim safety data paves the way...

Intervju

Ultimovac's study in malignant melanoma is fully recruited

Despite challenges related to the pandemic, Norwegian biotech company...

BioInvent delivered in 2021 with more to come in 2022

The Swedish biotechnology company BioInvent recently published its year-end report,...

Intervju

Strengthened clinical validation of Ultimovacs UV1 in the second quarter

For Norwegian Ultimovacs, the second quarter of the year was about...

Intervju

Ultimovacs presented clinical data at ASCO

At the virtual ASCO conference that just concluded,...

New data supports Ultimovac's cancer vaccine

It seems like Ultimovacs is on to something...

Immunicum updates clinical development strategy

Since Sven Rohmann took over as CEO of...

Ultimovacs takes up the fight against melanoma

Melanoma is the deadliest form of skin cancer and...

Ultimovac's path towards a universal cancer vaccine

Cancers represent a heavy burden on society and...